P/E ratio for Psychemedics (PMD)
P/E ratio as of July 2025 (TTM): -3.75
According to Psychemedics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.7512. At the end of 2022 the company had a P/E ratio of -25.6.
P/E ratio history for Psychemedics from 2001 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -25.6 | -55.87% |
| 2021 | -58.1 | 695.57% |
| 2020 | -7.30 | -122.32% |
| 2019 | 32.7 | 71.71% |
| 2018 | 19.1 | 3.59% |
| 2017 | 18.4 | -8.5% |
| 2016 | 20.1 | -44.5% |
| 2015 | 36.2 | 43.42% |
| 2014 | 25.3 | 23.76% |
| 2013 | 20.4 | 8.18% |
| 2012 | 18.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 NeoGenomics
NEO | -8.61 | 129.43% | 🇺🇸 USA |
 Enzo Biochem ENZB | -3.24 | -13.54% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 21.0 | -658.89% | 🇺🇸 USA |
 LabCorp LH | 30.0 | -900.11% | 🇺🇸 USA |
 RadNet RDNT | -103 | 2,640.46% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.